Executive Summary
Edwards picked up an FDA clearance for the Triformis Resilia surgical tricuspid valve, a quiet but consequential move: the first dedicated Resilia-tissue tricuspid prosthesis hits the market just as transcatheter tricuspid therapy reaches ESC Class IIa status, forcing the open-surgical comparator to defend its territory with better hardware rather than guideline inertia. On the aortic side, a 134-patient German registry in Clinical Research in Cardiology showed that invasive transvalvular flow rate ≤200 mL/s reclassified low-gradient AS with adjusted OR 3.09 for likely-severe disease and matched 5-year mortality to high-gradient AS post-TAVI, sharpening pre-TAVI hemodynamic gatekeeping. Meanwhile, TD Cowen raised its Edwards price target citing TAVR share gains, even as Medtronic, Abbott, and Boston Scientific sit at 6-month lows — which tightens Edwards' moat across both surgical and transcatheter tricuspid plays heading into July earnings.
- Invasive TFR ≤200 mL/s identified likely-severe low-gradient AS independently of SVi, with adjusted HR 0.45 for 5-year cardiac mortality after TAVI (Clin Res Cardiol).
- Cardiac Damage Staging at 1-year post-TAVR predicted all-cause mortality (adj HR 1.90); AF and mild TR were the principal drivers of staging worsening in 762 patients (Cardiovasc Interv Ther).
- FDA cleared the Edwards Triformis Resilia surgical tricuspid prosthesis, expanding bovine-pericardial anti-calcification tissue to the right side (MassDevice).
- A first-in-human percutaneous BATAC closure technique delivered 100% technical success across 12 transaxillary TAVI cases with no major vascular complications (Am J Cardiol).
- A 232-patient CT-radiomics model predicted adverse LV remodeling post-TAVR with AUC 0.91 when post-procedural gradient was included, beyond conventional geometry (AUC 0.62) (medRxiv).
What to watch: New York Valves 2026 (June 24–26) will release late-breaking structural heart trials, and Medtronic reports earnings tomorrow (June 3) with consensus at $1.55 EPS — a barometer for the broader structural-heart slump.
Aortic Valve (TAVR/TAVI)
Invasive hemodynamics still has a role in low-gradient AS, and today's data sharpens it. A single-center German registry (N=134) showed that invasively measured transvalvular flow rate ≤200 mL/s identified likely-severe AS (adj OR 3.09, 95% CI 1.30–7.34) and predicted lower 5-year cardiac mortality after TAVI (adj HR 0.40) — performance that stroke-volume index alone failed to deliver. 77.3% of patients with "preserved" SVi >35 mL/m² nonetheless had low TFR, meaning conventional echo screening misses a real subset of severe AS. Single-center, retrospective, N=134. The 2025 ESC guidelines anchor low-flow low-gradient adjudication on stress echo and CT calcium scoring (>2000 AU males, >1200 AU females); invasive TFR is absent from the algorithm, but this signal will pressure that omission.
A 762-patient TAVR registry in Cardiovasc Interv Ther confirmed that Cardiac Damage Staging evolves out to one year — 58% of advanced-stage patients improved, while 7.1% of early-stage patients worsened — and 1-year advanced staging carried adj HR 1.90 for all-cause mortality. AF and TR drove the worsening trajectory, reinforcing that left-sided fixes don't rescue right-heart disease. ESC 2025 and ACC/AHA 2020 both flag concomitant TR as a key driver of adverse outcomes, with TV surgery recommended at the time of left-sided operations for severe TR (Class I, both guidelines).
In 12 percutaneous transaxillary TAVI cases, the BATAC balloon-assisted closure achieved 100% technical success and 91.7% device success without major vascular events. Surgical cutdown remains the standard for transaxillary access; N=12 makes this hypothesis-generating only.
Tricuspid Valve (TriClip, TTVR)
Edwards' FDA clearance of the Triformis Resilia surgical tricuspid valve is the surgical comparator's response to a transcatheter wave it can't ignore. ESC 2025 elevated TV surgery for symptomatic primary TR to Class I while simultaneously granting transcatheter TR treatment Class IIa (LOE A) for high-risk patients — built on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II. Those two recommendations now sit in direct tension, and better surgical tissue is how the open-heart camp competes.
The Triformis launch extends Resilia anti-calcification technology, validated on the aortic side with multi-year RESILIENCE data, to the tricuspid position where isolated surgical mortality has historically run 8–20% and late SVD has been undercharacterized because operative volumes are low and follow-up limited. Whether improved tissue durability shifts referral patterns away from medical therapy — the dominant choice until end-organ damage arrives — is the unanswered question. ACC/AHA 2020 did not address transcatheter TR; the next US update will need to reckon with both catheter-based options and what a better surgical prosthesis does to the comparison.
Real-world TTVR data from the STS/ACC TVT Registry in 1,034 EVOQUE cases showed 3.1% 30-day mortality and 97.7% TR reduction to ≤mild — better than the randomized TRISCEND II safety signal, though selection bias in early-adopter centers is the obvious caveat. That caveat matters: registry patients are not randomized, and favorable operator experience inflates success rates in ways that won't generalize to lower-volume programs.
Mitral Valve (MitraClip, PASCAL, TMVR)
No new mitral outcomes data today. One regulatory note: CASSINI-US (NCT07130994), the early feasibility study of InnovHeart's SATURN TMVR system, moved to "not yet recruiting" status with a 15-patient target. SATURN joins a crowded TMVR development pipeline — Tendyne, Intrepid, EVOQUE, AltaValve, Cardiovalve — that has consistently struggled to demonstrate the durability and LVOT-obstruction safety needed to compete with surgical mitral repair, which both ACC/AHA 2020 and ESC 2025 maintain as Class I for primary MR. The ESC's upgrade of TEER to Class I for ventricular secondary MR (from ACC/AHA's Class IIa) means TMVR's commercial case must be built against an increasingly entrenched clip-based standard, not against surgery. SATURN will need to clear both bars.
Surgical vs. Transcatheter Comparisons
The Triformis Resilia tricuspid clearance is a surgical answer in a transcatheter conversation; today's other findings — TFR-based AS adjudication, post-TAVR cardiac damage staging trajectories, percutaneous axillary closure — are transcatheter-side refinements without a surgical comparator in the underlying data. The ESC 2025 framework is worth keeping front: SAVR is preferred under age 70 with low surgical risk (STS-PROM + EuroSCORE II <4%), TAVI is preferred at ≥70 with suitable transfemoral anatomy. ACC/AHA 2020 thresholds (<65 SAVR, >80 TAVI, 65–80 shared decision) remain the operative US framework. TD Cowen's bullish Edwards thesis on TAVR share growth doesn't change the durability arithmetic that keeps younger patients in the SAVR column on both sides of the Atlantic.
Preprint Highlights
A 232-patient retrospective TAVR cohort on medRxiv used CT-derived myocardial radiomics plus clinical variables to predict adverse LV remodeling (defined as ≥10% LVMI increase at follow-up; 22.4% incidence). Geometry alone underperformed (AUC 0.62); adding wall-thickness radiomics pushed AUC to 0.84, and the full pre-procedural multimodal model hit AUC 0.86 (95% CI 0.73–0.98). Adding post-procedural mean gradient raised it to AUC 0.91. SHAP analysis identified residual gradient and myocardial heterogeneity as the dominant predictors. Retrospective, single-cohort, no prospective validation — the critical limitation is whether radiomic features hold across CT scanners and vendors. The practical promise: CT scans acquired routinely for TAVR planning could carry double duty as myocardial risk stratifiers without additional image acquisition.
Device & Technology
Two technology threads. First, the BATAC percutaneous transaxillary closure technique — balloon inflation at the arteriotomy site while ProStyle suture knots are sequentially advanced under fluoroscopy — addresses a real bottleneck for alternative-access TAVI. Surgical cutdown for transaxillary access remains the norm and adds operative time, infection risk, and general anesthesia burden. Twelve cases is preliminary; larger registries will determine whether this generalizes outside experienced operators. Second, the Triformis Resilia launch brings the same RESILIENCE-validated anti-calcification chemistry that has extended Edwards' surgical aortic valve performance to the tricuspid position, where late SVD has been undercharacterized because operative volumes are low and follow-up limited.
Regulatory & Policy
FDA cleared the Edwards Triformis Resilia surgical tricuspid valve replacement, the first dedicated Resilia-tissue prosthesis purpose-built for the tricuspid position. The clearance closes an obvious portfolio gap and arrives precisely when transcatheter tricuspid options (EVOQUE TTVR, TriClip M-TEER) are expanding under ESC Class IIa endorsement. Edwards now competes against itself in tricuspid disease — a familiar position given its dual aortic franchise.
Industry & Market
TD Cowen lifted its Edwards Lifesciences price target, citing TAVR market share gains against Medtronic. The thesis squares with the diverging six-month price action: EW +4.4% versus MDT –26.5%. Harlingen Medical Center performed its first TAVR procedure, a routine but telling marker of how TAVR continues penetrating mid-volume regional hospitals — relevant context for the Canadian ATLAS trial (NCT06818006), which will test TAVI at experienced cath labs without on-site cardiac surgery (N=600, Phase 4). A positive ATLAS readout would expand the addressable site count materially, and Edwards is best positioned to capture it.
Financial Analysis
The structural heart sector is bifurcating. Edwards' tight focus on the valve franchise — now spanning surgical aortic (Inspiris Resilia), surgical mitral, surgical tricuspid (Triformis), TAVR (SAPIEN), TEER (PASCAL), and TTVR (EVOQUE) — is being rewarded as competitors trade at multi-quarter lows. Boston Scientific is off 51.6% over six months despite a strong-buy consensus and a $79.37 target; Abbott is off 29.8% and Medtronic 26.6%. The market is pricing concerns that extend beyond structural heart, but the valve franchise is one of the few growth engines valued positively in the group. The Triformis clearance and TD Cowen's TAVR upgrade reinforce that Edwards' moat is widening clinically even as the broader medtech tape stays heavy. Anteris (AVR.AX) continues its outlier rally — up 105% over six months on the DurAVR single-piece bovine pericardial THV story — though with only one analyst covering the name and a $1.3B market cap, this remains a speculative thesis tied to early clinical signals.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $87.66 (–0.57%); 6-month: +4.38%; 52-week range $72.30–$89.14
- Market cap $50.5B; trailing P/E 47.4; forward P/E 26.0; beta 0.87
- Analyst target $96.65 (26 analysts), buy consensus
- Next earnings July 23 (EPS $0.74, revenue $1.70B est.)
- Triformis Resilia tricuspid FDA clearance and TD Cowen target hike both landed today; EW now owns surgical and transcatheter franchises across all three valves.
Medtronic (MDT)
- Close: $73.75 (–0.31%); 6-month: –26.55%; 52-week range $73.31–$106.33
- Market cap $94.7B; trailing P/E 20.6; forward P/E 12.2; beta 0.63
- Analyst target $106.56 (25 analysts), buy consensus
- Next earnings tomorrow (June 3) — EPS $1.55, revenue $9.61B est.
- Stock at six-month lows ahead of print; Evolut share losses to SAPIEN are central to the bear case, and tomorrow's commentary on structural heart growth will set the tone for the sector.
Abbott (ABT)
- Close: $86.97 (–0.92%); 6-month: –29.80%; 52-week range $81.97–$139.06
- Market cap $151.5B; trailing P/E 24.4; forward P/E 14.4; beta 0.65
- Analyst target $117.29 (24 analysts), buy consensus
- Next earnings July 16 (EPS $1.28, revenue $12.53B est.)
- Structural heart story rests on Navitor TAVR (limited US share), TriClip (Class IIa ESC tailwind), and Tendyne TMVR pipeline. Stock weakness reflects broader sentiment more than structural heart specifics.
Boston Scientific (BSX)
- Close: $47.68 (–0.63%); 6-month: –51.63%; 52-week range $47.35–$109.50
- Market cap $70.9B; trailing P/E 20.0; forward P/E 12.8; beta 0.62
- Analyst target $79.37 (30 analysts), strong-buy consensus
- Next earnings July 29 (EPS $0.83, revenue $5.38B est.)
- ACURATE neo2 post-market data has weighed on sentiment; strong-buy consensus reflects belief that the watchman + EP franchise carries the company through any TAVR setback.
Anteris Technologies (AVR.AX)
- Close: A$13.00 (+4.00%); 6-month: +105.37%; 52-week range A$4.68–A$13.80
- Market cap A$1.3B; forward P/E –5.96 (pre-revenue); beta 0.59
- Analyst target A$13.00 (1 analyst)
- DurAVR single-piece bovine pericardial THV continues to attract clinical interest; commercialization timeline remains the open question.
Market outlook: The valve industry tape is a tale of one stock. Edwards has separated from the medtech pack on the strength of a pure-play valve franchise that now spans every chamber and every access route. Medtronic's print tomorrow is the next test for the broader sector — a soft structural heart commentary would deepen the rotation into EW, while an upside surprise could trigger the first meaningful rally for MDT in months.
Clinical Trial Updates
Aortic
- ATLAS Study (NCT06818006) — TAVI at experienced interventional centers without on-site cardiac surgery. Phase 4, N=600, not yet recruiting. Sponsor: University of Alberta. [NOTABLE] A positive readout would expand US and Canadian site eligibility well beyond traditional cardiac surgery centers, with major implications for both TAVR market expansion and the surgical safety net argument that has historically required on-site backup.
Mitral Replacement
- CASSINI-US (NCT07130994) — SATURN TMVR system for mitral regurgitation. Early feasibility, N=15, not yet recruiting. Sponsor: InnovHeart. Adds another entrant to a TMVR pipeline that has yet to produce a commercially approved US device; the small-N feasibility design confirms this remains early-stage development.
Medtronic reports tomorrow, New York Valves 2026 begins its run-up to late-breaker week the day after. The combination — a structural-heart bellwether print followed by a major scientific session — will determine whether today's Triformis clearance and TD Cowen upgrade represent a tactical Edwards moment or a structural reshuffling of the valve industry's competitive map.
— E. Nolan Beckett, MD